Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational studyLeticia Monin, Sheeba Irshad, Shraddha Kamdar et al.|The Lancet Oncology|2021Cited by 614
Factors Affecting COVID-19 Outcomes in Cancer Patients: A First Report From Guy's Cancer Center in LondonBeth Russell, Mieke Van Hemelrijck, Charlotte Moss et al.|Frontiers in Oncology|2020Cited by 64
Interim results of the safety and immune-efficacy of 1 versus 2 doses of COVID-19 vaccine BNT162b2 for cancer patients in the context of the UK vaccine priority guidelinesLeticia Monin, Sheeba Irshad, Adam G. Laing et al.|medRxiv|2021Cited by 61
Risk of COVID-19 death in cancer patients: an analysis from Guy’s Cancer Centre and King’s College Hospital in LondonBeth Russell, Kavita Raj, Charlotte Moss et al.|British Journal of Cancer|2021Cited by 59
The Impact of COVID-19 on the Delivery of Systemic Anti-Cancer Treatment at Guy’s Cancer CentreBeth Russell, Saoirse Dolly, Charlotte Moss et al.|Cancers|2022Cited by 4